Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)

ClinicalTrials.gov ID: NCT01222702

Public ClinicalTrials.gov record NCT01222702. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of a 10-day Twice Daily Oral Administration of Three Doses of Cadazolid (ACT-179811) in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Cadazolid is a new antibiotic developed for the treatment of Clostridiun difficile associated diarrhea (CDAD), also known as Clostridium Difficile Infection (CDI). The purpose of the study was to evaluate the efficacy and safety of different doses of cadazolid in order to find the dose of cadazolid to be used for further clinical development of the compound in subjects with CDAD.

Study identification

NCT ID: NCT01222702
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Actelion; Industry
Enrollment: 84 participants

Conditions and interventions

Conditions

Clostridium Difficile Infection

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 24, 2011
Primary completion: Oct 15, 2012
Completion: Nov 11, 2012
Last update posted: Jun 13, 2017

2011 – 2012

United States locations

U.S. sites: 11
U.S. states: 9
U.S. cities: 11

Facility	City	State	ZIP	Site status
Clinical Investigative Site 6902	Newark	Delaware	19718	—
Clinical Investigative Site 6919	Jacksonville	Florida	32207	—
Clinical Investigative Site 6938	Orlando	Florida	32837	—
Clinical Investigative Site 6930	Decatur	Georgia	30033	—
Clinical Investigative Site 6935	Marietta	Georgia	30060	—
Clinical Investigative Site 6915	Idaho Falls	Idaho	83404	—
Clinical Investigative Site 6906	Chicago	Illinois	60637	—
Clinical Investigative Site 6917	Boston	Massachusetts	02111	—
Clinical Investigative Site 6936	Royal Oak	Michigan	48073	—
Clinical Investigative Site 6903	Columbus	Ohio	43215	—
Clinical Investigative Site 6914	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01222702, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 13, 2017 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01222702 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →